Herein, six new heterocyclic compounds have been successfully synthesized and tested for biological function. The synthesis was started with the pharmaceutical molecule flucytosine, which has a primary amine group. This compound was reacted with an aldehyde and a ketone in absolute ethanol to produce two new Schiff bases (R1 and R2). As a result, these Schiff bases with an azomethine group functioned as important intermediates in the synthesis of two separate types of heterocyclic compounds. First, R1 and R2 were treated to produce a set of tetracyclic β-lactam derivatives (R3 and R4), which were then reacted in 1,4-dioxane. Second, the identical Schiff bases were used to create various seven-membered heterocyclic compounds, including oxazepine derivatives (R5 and R6). Thin-Layer Chromatography (TLC) was used to monitor the entire reaction process, and the purity of the resulting compounds was validated by determining their melting points. The structures of all new derivatives were carefully described utilizing spectroscopic techniques such as Fourier-Transform Infrared (FTIR) Spectroscopy, 1 H-NMR, and 13C-NMR Spectroscopy. Finally, the biological activity of the produced R1-R6 derivatives was thoroughly studied. The antibacterial capability of these compounds was evaluated against grampositive and gram-negative microbes. The findings revealed that the bulk of the generated chemicals had excellent antibacterial activity. The compounds R1 and R4 are especially efficient against Klebsiella pneumoniae and E. faecalis.
Hussein et al. (Thu,) studied this question.